Zynamite granted U.S. patent for supporting cognitive health
Zynamite, a proprietary standardized extract of leaves of Mangifera indica, has been granted U.S. Patent 10,537,604 for Compositions for Enhancing Brain Activity.
Photo © Shutterstock.com/jovan vitanovski
Zynamite, a proprietary standardized extract of leaves of Mangifera indica, manufactured by Nektium (Las Palma, Spain) and distributed by PLT Health Solutions in the U.S., has been granted U.S. Patent 10,537,604 for Compositions for Enhancing Brain Activity. The ingredient supports mental and physical energy, and has been studied in sports formulations in four double-blind, randomized, placebo-controlled clinical trials.
"The currency of the nutraceutical ingredient industry is scientific evidence obtained from double-blind, randomized, controlled clinical studies conducted by reputable academic departments and CRO's, and published in leading peer-reviewed journals. Nektium has made a major investment in the clinical research backing Zynamite and continues to invest in ongoing clinical studies," said Nigel Gericke, PhD, Nektium's director of science, in a press release. "Our intention is to keep building the clinical research base and intellectual property supporting Zynamite as a premium branded ingredient."
New review paper highlights gut-brain benefits of novel herbal blend, Digexin
September 16th 2024NXT USA has announced the publication of a narrative review that offers an in-depth analysis of the efficacy and safety of its Digexin ingredient, which is a novel blend of Ashwagandha and okra extracts.
